ESR1 and breast carcinoma: Our research demonstrates that, in breast cancers, CK2 signaling is associated with elevated ER expression and tamoxifen resistance, and that pharmacological inhibition with CX can disrupt ERα overexpression and, therefore, cancer cell viability.